HORMONE-RECEPTOR -POSITIVE BREAST CANCER: DIFFERENT PROGNOSIS OF BONE METASTASIS AMONG MOLECULAR SUBTYPES

The aim of study was identification of bone metastasis probability, in molecular subtypes among post-treated patients (hormone-receptor-positive breast cancer), considering statistical frequency of stages. 101 women (I, II, III stages; hormone-receptor-positive), who underwent bone scintigraphy before and after treatment, were retrospectively studied. The study was performed with radiotracer Tc99m MDP, intravenous injection. BS data were correlated with molecular subtype (Luminal-A, Luminal-B) and stage. According to the stages, molecular subtypes and bone metastasis was revealed: In the I stage - 32 (20,0%) patients: luminal A - 30 (93.7%) patients, among them with metastasis 12 (40%) cases; luminal B - 2 (6.2%) patients with metastasis 0 (0%) cases (p=0.282). II stage - 83 (51.9%) patients: luminal A = 71 (85.5%) patients, among them with metastasis - 43 (60.5%) cases; luminal B - 12 (14.4%) patients; among them with metastasis -3 (25%) cases (p=0.022) III stage =45 (28.1%) patients: Luminal A 38 (84.4%) patients, among them with metastasis - 30 (78.9%) cases; luminal B - 7 (15.5%) patients; among them with metastasis - 1 (14.2%) case (p=0.001). Among breast cancer patients' molecular subtype luminal A has a high probability of spreading metastasis in bone, but there is more positive prognosis, rather than in luminal B type, that is much rarer and more aggressive molecular subtype. Taking into consideration molecular subtypes and stages of breast cancer is very important, as both of them are significant prognostic factors of disease, which might be helpful in the most cases.